Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Biotech investors are always looking for the next big thing. That's exactly what they found in Exelixis (NASDAQ: EXEL), which ranked as one of the top biotech stocks of 2016 (and 2015 also). But Exelixis isn't the little biotech ready to hit the big time anymore. Intra-Cellular Therapies (NASDAQ: ITCI) could be, though.
Intra-Cellular Therapies stock has taken investors on a roller coaster ride so far in 2017. Exelixis has continued its winning ways of prior years. Which stock is now the better buy?
Image source: Getty Images.
Source: Fool.com
Exelixis Inc. Aktie
46,32 €
1,13 %
Die Exelixis Inc. Aktie erhält mehrere Buy-Einschätzungen, übersteigt die Sell-Zahlen.
Obwohl das Kursziel von 43 € für Exelixis Inc. den aktuellen Kurs von 46.32 € unterschreitet, zeigt sich ein negatives Potenzial von -7.17%.
